Tango Therapeutics appoints Malte Peters CEO as founder Barbara Weber becomes Executive Chair; cash $343M

Tango Therapeutics, Inc.

Barbara Weber, M.D. retires as President and CEO effective Jan 8, 2026; becomes Executive Chair through 2026.
Malte Peters, M.D., board member since 2018, named President and CEO; granted 1.65M options and 350K RSUs.
Cash, cash equivalents and marketable securities totaled $343M as of Dec 31, 2025 (unaudited).
2026 milestones reiterated: vopimetostat combos data, lung cancer update, pancreatic pivotal start, TNG456 data.
Alexis Borisy transitions from Board Chair to Lead Independent Director.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.